| Literature DB >> 31029107 |
Janet M J Been-Dahmen1,2, Denise K Beck2, Mariëlle A C Peeters1,3, Heleen van der Stege1, Mirjam Tielen2, Marleen C van Buren2, Erwin Ista4,5, AnneLoes van Staa1,3, Emma K Massey6.
Abstract
BACKGROUND: To support effective self-management after kidney transplantation, a holistic nurse-led self-management support intervention was developed using the Intervention Mapping approach. The primary aim was to evaluate the feasibility, acceptability and fidelity of the intervention for kidney transplant recipients and professionals. The secondary aim was to explore preliminary effects on outcomes.Entities:
Keywords: End-stage-renal disease; Intervention evaluation; Nurse practitioner; Nursing; Organ transplantation; Pilot study; Self-care; Self-management support
Mesh:
Year: 2019 PMID: 31029107 PMCID: PMC6486974 DOI: 10.1186/s12882-019-1300-7
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.585
Research questions and data-collection methods
| Research questions | Data-collection techniques | ||||
|---|---|---|---|---|---|
| Quantitative | N intervention group (T0/ T1) | N control group (T1) | Qualitative | N | |
|
| Therapy Adherence Measurement (TAM- score) | 16a | Observations | 6 | |
|
| Questionnaire to rate areas recipients perceived to be important and which areas were addressed during the consultation with the nurse | 16 | 33 | Individual interviews with patients | 11 |
| Individual interviews with Nurse Practitioners | 2 | ||||
| Individual interviews with doctors | 2 | ||||
|
| Questionnaire (T0-T1) | 16 | |||
|
| Questionnaire (T1 intervention –control) | 16 | 33 | ||
aOnly measured at T1
Fig. 1Self-management Web
Outcome measures and questionnaires
| Primary outcome | Secondary outcomes | Questionnaire |
|---|---|---|
| Self-management knowledge and behaviour | - Partners in Health Scale (PIH) [ | |
| Quality of life | - 36-Item Short Form Survey (SF-36) [ | |
| Self-efficacy | - Visual Analogue Scales (VAS) | |
| Feelings after kidney transplantation | - The Transplant Effects Questionnaire (TxEQ) [ | |
| Quality of nurse-led care | - American Consumer Assessment of Health Plan Surveys (CAHPS) [ | |
| Social support | - Health Education Impact Questionnaire (heiQ) [ | |
| NPs’ fidelity to intervention protocol | - Therapy Adherence Measurement (TAM) [ | |
| Importance vs actual attention to topic during nurse-led consultation session | - Self-developed questionnaire |
Fig. 2Flow chart of participants in the intervention group
Sample characteristics
| Characteristics | Control group | Intervention group |
|---|---|---|
| Age (median; IQR) | 59.8; IQR 29.4–75.8 | 59.7; IQR 28.7–72.2 |
| Gender | ||
| Male (n; %) | 22 (66.7) | 17 (70.9%) |
| Marital status | ||
| Married/ living together (yes; n; %) | 21 (63,6) | 11 (46.9%)b |
| In paid employment yes; (n; %) | 10 (30.3) | 9 (37.5%) |
| Highest educational attainment (n; %) | a | b |
| None | 1 (3.0) | 1 (4.2%) |
| Primary school | 3 (9.0) | 1 (4.2%) |
| Secondary School | 9 (27.3) | 7 (29.1%) |
| Higher education | 18 (54.5) | 12 (50%) |
| Number of transplantations (n; %) | a | b |
| 1 | 26 (78.8) | 21 (87.5) |
| 2 | 4 (12.1) | 3 (12.5) |
| 3 | 3 (9.1) | 0 (0) |
| Ethnicity (n; %) | a | |
| African | 3 (9.1) | 5 (20.8) |
| Asian | 4 (12.1) | 2 (8.3) |
| European | 22 (66.8) | 16 (66.7) |
| South American | 0 (0) | 1 (4.2) |
| Turkish | 2 (6.0) | 0 |
| Dialysis before transplantation (n; %) | ||
| Yes | 21 (63.6) | 17 (70.8) |
| No | 12 (36.4) | 7 (29.2) |
| Comorbidity (n; %) | ||
| Diabetes | 9 (27.3) | 6 (25.0) |
| Cardiac Event | 6 (18.2) | 5 (20.8) |
| CVA event | 5 (15.2) | 1 (4.1) |
| Vascular Event | 3 (9.1) | 1 (4.1) |
amissings (n = 2)
bmissings (n = 3)
Importance of paying attention and actual attention paid to various topics
| Topics | Answer options | Area perceived to be important (N; %) | Answer options | Area of importance addressed by NP (N; %) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T0 | T1 | C | T0 | T1 | C | |||||||
| (Unpaid) work or education | Not important | 7 (46.7) | 5 (31.3) | 15 (50.0) | 0.380 | 0.384 | Not addressed | 7 (53.9) | 4 (26.7) | 19 (63.3) | 0.083 | 0.012 |
| Important | 8 (53.3)a | 11 (68.8) | 15 (50.0)c | Addressed | 6 (46.1)c | 11 (73.3)a | 11 (36.7)c | |||||
| Social contacts and relationships | Not important | 3(20.0) | 4 (25.0) | 13 (43.3) | 0.763 | 0.239 | Not addressed | 6 (46.1) | 4 (26.7) | 16 (51.6) | 0.052 | 0.000 |
| Important | 12 (80.0)a | 12 (75.0) | 17 (56.7)c | Addressed | 7 (53.9)c | 11 (73.3)a | 15 (48.4)b | |||||
| Sexuality | Not important | 8 (53.3) | 5 (31.3) | 21 (70.0) | 0.166 | 0.016 | Not addressed | 9 (69.2) | 6 (40.0) | 27 (87.1) | 0.096 | 0.002 |
| Important | 7 (46.7)a | 11 (56.8) | 9 (30.0)c | Addressed | 4 (30.8)c | 9 (60.0)a | 4 (12.9)b | |||||
| (Adjustment of) leisure activities | Not important | 0 (0.0) | 2 (12.5) | 12 (40.0) | 0.527 | 0.036 | Not addressed | 2 (16.7) | 1 (6.3) | 17 (54.8) | 0.257 | 0.002 |
| Important | 15 (100.0)a | 14 (87.5) | 18 (60.0)c | Addressed | 10 (83.3)d | 15 (93.7) | 14 (45.2)b | |||||
| Practical matters in daily life (e.g. household) | Not important | 4 (26.7) | 3 (18.8) | 13 (41.9) | 0.132 | 0.088 | Not addressed | 3 (23.1) | 3 (20.0) | 21 (72.4) | 0.564 | 0.001 |
| Important | 11 (73.3)a | 13 (81.2) | 18 (58.1)b | Addressed | 10 (76.9)c | 12 (80.0)* | 8 (27.6)d | |||||
| Transport and mobility | Not important | 5 (33.3) | 6 (37.5) | 16 (53.3) | 0.803 | 0.455 | Not addressed | 5 (28.5) | 5 (33.3) | 21 (72.4) | 0.705 | 0.009 |
| Important | 10 (66.7)a | 10 (62.5) | 14 (46.7)c | Addressed | 8 (61.5)c | 10 (66.7)* | 8 (27.6)d | |||||
| Personal care (e.g. washing, dressing) | Not important | 7 (46.7) | 5 (31.3) | 13 (43.3) | 0.160 | 0.671 | Not addressed | 8 (57.1) | 5 (31.3) | 20 (66.7) | 0.057 | 0.005 |
| Important | 8 (53.3) a | 11 (68.7) | 17 (56.7)c | Addressed | 6 (42.9)b | 11 (68.7) | 10 (33.3)c | |||||
| Adjusting lifestyle (e.g. nutrition, exercise) | Not important | 2 (20.0) | 1 (6.3) | 9 (30.0) | 0.527 | 0.038 | Not addressed | 4 (30.8) | 2 (12.5) | 11 (37.9) | 0.107 | 0.009 |
| Important | 13 (80.0)a | 15 (93.7) | 21 (70.0)c | Addressed | 9 (69.2)c | 14 (87.5) | 18 (62.1)d | |||||
| Psychological well-being | Not important | 1 (6.7) | 2 (12.5) | 7 (23.3) | 0.783 | 0.003 | Not addressed | 5 (35.7) | 2 (12.5) | 16 (55.2) | 0.021 | 0.003 |
| Important | 14 (93.3)a | 14 (87.5) | 23 (76.7)c | Addressed | 9 (64.3)b | 14 (87.5) | 13 (44.8)d | |||||
| Dealing with the chronic condition | Not important | 1 (6.7) | 1 (6.7) | 3 (9.7) | 0.564 | 0.167 | Not addressed | 2 (14.3) | 0 (0.0) | 11 (37.9) | 0.025 | 0.001 |
| Important | 14 (93.3)a | 14 (93.3)a | 28 (90.3)b | Addressed | 12 (85.7)b | 16 (100.0) | 18 (62.1)d | |||||
| Dealing with lack of understanding of others | Not important | 5 (33.3) | 2 (13.3) | 10 (32.3) | 0.119 | 0.015 | Not addressed | 9 (64.3) | 5 (33.3) | 21 (72.4) | 0.053 | 0.002 |
| Important | 10 (66.7)a | 13 (86.7)a | 21 (67.7)b | Addressed | 5 (35.7)b | 10 (66.7)a | 8 (27.6)d | |||||
| (re)inting normal life | Not important | 1 (6.7) | 2 (12.5) | 3 (9.7) | 1.00 | 0.030 | Not addressed | 3 (21.4) | 1 (6.3) | 12 (40.0) | 0.046 | 0.000 |
| Important | 14 (93.3)a | 14 (87.5) | 28 (90.3)b | Addressed | 11 (78.6)b | 15 (93.7) | 18 (60.0)c | |||||
| Medical issues around the condition | Not important | 2 (13.3) | 1 (6.3) | 2 (6.4) | 0.564 | 0.922 | Not addressed | 2 (14.3) | 0 (0) | 2 (7.1) | 0.157 | 0.022 |
| Important | 13 (86.7)a | 15 (93.7) | 29 (93.6)b | Addressed | 12 (85.7)b | 16 (100.0) | 26 (92.9)e | |||||
| Referral to other health care professionals (if needed) | Not important | 5 (33.3) | 1 (6.3) | 1 (3.1) | 0.480 | 0.446 | Not addressed | 1 (7.2) | 1 (6.3) | 8 (26.7) | 0.083 | 0.044 |
| Important | 10 (66.7)a | 15 (93.7) | 31 (96.9)a | Addressed | 13 (92.9)b | 15 (93.7) | 22 (73.3)c | |||||
| Being in control with own treatment process | Not important | 1 (6.7) | 0 (0.0) | 1 (3.1) | 0.480 | 0.216 | Not addressed | 1 (7.2) | 1 (6.3) | 10 (35.3) | 0.046 | 0.002 |
| Important | 14 (86.7)a | 16 (100.0) | 31 (96.9)a | Addressed | 13 (92.9)b | 15 (93.7) | 20 (66.7)c | |||||
a missing (n = 1)
bmissings (n = 2)
cmissings (n = 3)
dmissings (n = 4)
emissings (n = 5)
Medians, interquartile ranges and p-values of the primary and secondary outcomes
| Outcomes | Subdomain (questionnaire) | T0a | T1a | Ca | P-value (Wilcoxon test) | Effect Size | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Median (IQR) | N | Median (IQR) | N | Median (IQR) | C-T1 | T0-T1 | C-T1 | T0-T1 | ||
| Self-management knowledge and behaviour | Total Score (PIHb) | 15 | 88.0 (81.0–92.0) | 15 | 88.0 (81.0–94.0) | 32 | 85.5 (80.0–93.0) | 0.54 | 0.41 | 0.20 | 0.24 |
| Self-management knowledge and behaviour | Knowledge and coping (PIHb) | 15 | 51.0 (41.0–53.0) | 15 | 51.0 (45.0–55.0) | 33 | 47.0 (42.0–54.5) | 0.47 | 0.43 | 0.23 | 0.27 |
| Self-management knowledge and behaviour | Recognition and management of symptoms, adherence to treatment (PIHb) | 15 | 38.0 (36.0–40.0) | 15 | 38.0 (36.0–40.0) | 32 | 38.5 (36.0–40.0) | 0.89 | 0.69 | 0.18 | 0.09 |
| Quality of Life | General quality of life (WHOQol-BREFb) | 16 | 4.0 (3.0–4.0) | 16 | 4.0 (3.0–4.0) | 32 | 4.0 (3.0–4.0) | 0.73 | 0.56 | 0.20 | 0.22 |
| Quality of Life | Satisfaction with health (WHOQol-BREFb) | 16 | 3.0 (2.0–4.0) | 16 | 3.5 (3.0–4.0) | 33 | 4.0 (3.0–4.0) | 0.27 | 0.40 | − 0.31 | 0.11 |
| Quality of Life | Role limitations due to physical health problems (SF-36b) | 15 | 0.0 (0.0–50.0) | 15 | 75.0 (0.0–100.0) | 30 | 87.5 (0.0–100.0) | 0.78 | 0.02 | − 0.11 | 0.78 |
| Quality of Life | Role limitations due to emotional problems (SF-36b) | 14 | 100.0 (0.25–100.0) | 15 | 100.0 (50.00–100.0) | 29 | 100.0 (66.7–100.0) | 0.55 | 0.73 | − 0.17 | 0.14 |
| Quality of Life | Vitality (SF-36b) | 16 | 50.0 (26.3–58.8) | 16 | 32.5 (25.8–52.5) | 32 | 42.5 (25.0–53.8) | 0.58 | 0.03 | − 0.14 | −0.41 |
| Quality of Life | General mental health (SF-36b) | 16 | 75.5 (61.5–88.0) | 16 | 84.0 (70.5–92.0) | 32 | 87.5 (64.0–92.0) | 0.75 | 0.27 | 0.11 | 0.27 |
| Self-efficacy | Total score (SECD6b) | 16 | 5.3 (3.2–7.2) | 16 | 5.3 (2.8–7.6) | 30 | 5.6 (3.8–7.3) | 0.94 | 0.32 | −0.04 | 0.20 |
| Self-efficacy | VAS - healthb | 16 | 60.1 (32.6–81.1) | 16 | 66.9 (50.7–79.8) | 32 | 70.5 (53.8–80.6) | 0.70 | 0.25 | − 0.13 | 0.31 |
| Self-efficacy | VAS -painb | 16 | 8.3 (2.5–36.0) | 16 | 3,6 (0.4–25.7) | 33 | 2.9 (0.7–14.0) | 0.99 | 0.90 | 0.05 | 0.20 |
| Self-efficacy | VAS - fatigueb | 16 | 57.2 (9.4–74.5) | 16 | 25.7 (19.6–65.5) | 33 | 43.9 (8.6–61.9) | 0.82 | 0.45 | − 0.08 | 0.20 |
| Transplant effects | Worry about the transplan (TxEQb) | 14 | 3.4 (2.5–4.0) | 16 | 3.1 (2.6–3.5) | 29 | 3.3 (2.7–3.7) | 0.69 | 0.69 | 0.11 | 0.48 |
| Transplant effects | Guilt towards the donor (TxEQb) | 16 | 2.1 (1.8–2.6) | 16 | 2.0 (1.6–2.2) | 33 | 2.2 (1.8–2.8) | 0.08 | 0.07 | 0.54 | 0.34 |
| Transplant effects | Disclosure about the transplantation (TxEQb) | 16 | 5.0 (4.0–5.0) | 16 | 4.8 (4.4–5.0) | 32 | 4.8 (3.7–5.0) | 0.85 | 0.07 | − 0.01 | 0.31 |
| Transplant effects | Adherence to immunosuppressive medications (TxEQb) | 16 | 4.8 (4.4–5.0) | 16 | 5.0 (4.6–5.0) | 32 | 4.8 (4.1–5.0) | 0.03 | 0.12 | 0.81 | 0.43 |
| Transplant effects | Responsibility towards others (TxEQb) | 16 | 3.5 (3.0–4.0) | 16 | 3.6 (3.3–4.0) | 33 | 3.8 (3.0–4.3) | 0.86 | 0.36 | 0.02 | 0.20 |
| Social support | Social integration and support (heiQb) | 16 | 18.5 (13.5–20.0) | 16 | 19.0 (15.0–20.0) | 33 | 18.0 (15.0–20.0) | 0.78 | 0.91 | − 0.09 | −0.04 |
| Patient-centred care | Total score (CAHPSb) | 15 | 19.0 (18.0–20.0) | 15 | 20.0 (20.0–20.0) | 32 | 19.5 (18.0–20.0) | 0.05 | 0.02 | 0.56 | 0.56 |
aC Control group, T0 Intervention group at baseline, T1 Intervention group after receiving the intervention
bPIH Partners in health scale, WHOQol-BREF The world health organization quality of life - brief version, SF-36 36-item short form survey, SECD6 Self-efficacy for managing chronic disease 6-item scale, VAS Visual analogue scales, TxEQ The transplant effects questionnaire, heiQ Health education impact questionnaire, CAHPS American consumer assessment of health plan surveys